Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent

Journal of the American Academy of Dermatology

Volumn 46, Issue 6, 2002, Pages 945-947

  Koss, Tamara ^a   Bagheri, Bita ^a   Zeana, Cosmina ^b   Romagnoli, Mario F ^b   Grossman, Marc E ^a  

^a Division of Infectious Diseases   (United States)

^b New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTINEOPLASTIC AGENT; CASPOFUNGIN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MITOXANTRONE; MYELOTARG;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG RESPONSE; FEMALE; FUNGUS CULTURE; FUNGUS IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; NEUTROPENIA; PRIORITY JOURNAL; SKIN BIOPSY; SYMPTOM; THROMBOCYTHEMIA;

EID: 0036621551     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2002.120627     Document Type: Article

References (12)

1. Isaac M. Cutaneous aspergillosis. Dermatol Clin 1996;14:137-40.
2. Patel R, Paya CV. Infections in solid-organ transplant recipients. Clin Microbiol Rev 1997;10:86-124.
3. Grossman ME, Roth J. Cutaneous manifestations of infection in the immunocompromised host. Baltimore: Williams & Wilkins; 1995.
4. Emmanouilides C, Glaspy J. Opportunistic infections in oncologic patients. Hematol Oncol Clin North Am 1996;10:841-60.
5. Radentz WH. Opportunistic fungal infections in the immunocompromised host. J Am Acad Dermatol 1989;20:989-1003.
6. Schwartz S, Thiel E. Clinical presentation of invasive aspergillosis. Mycoses 1997;40:21-4.
7. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000;30:696-709.
8. 0 derivatives. J Med Chem 1994;37: 222-5.
9. Kurtz MB, Douglas C, Marhnan J, Nollstadt K, Onishi J, Dreikorn S, et al. The increased antifungal activity of L-733560, a water soluble semisynthetic pneumocandin, is due to enhanced inhibition of cell wall synthesis. Antimicrob Agents Chemother 1994; 38:2750-7.
10. Kurtz MB, Heath LB, Marinan J, Dreikorn S, Douglas C. Morphological effects of pneumocandins against Aspergillus fumigatus correlate with activity against (1,3)-β-D-glucan synthase. Antimicrob Agents Chemother 1994;38:1480-9.
11. Denning DW. Echinocandins and pneumocandins- a new antifungal class with a novel mode of action. J Antimicrob Chemother 1997;40:611-4.
12. Micromedex Healthcare Editorial Preview, Feb 2, 2001.